• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺癌患者中不同风险分层系统的基于人群的比较

Population-Based Comparison of Different Risk Stratification Systems Among Prostate Cancer Patients.

作者信息

Xie Mu, Gao Xian-Shu, Ma Ming-Wei, Gu Xiao-Bin, Li Hong-Zhen, Lyu Feng, Bai Yun, Chen Jia-Yan, Ren Xue-Ying, Liu Ming-Zhu

机构信息

Department of Radiation Oncology, Peking University First Hospital, Beijing, China.

Department of Radiation Oncology, Zhengzhou University First Affiliated Hospital, Zhengzhou, China.

出版信息

Front Oncol. 2021 Apr 13;11:646073. doi: 10.3389/fonc.2021.646073. eCollection 2021.

DOI:10.3389/fonc.2021.646073
PMID:33928035
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8076565/
Abstract

BACKGROUND

It is not known which risk stratification system has the best discrimination ability for predicting prostate cancer death.

METHODS

We identified patients with non-metastatic primary prostate adenocarcinoma diagnosis between 2004 and 2015 using the Surveillance, Epidemiology, and End Results database. Patients were categorized in different risk groups using the three frequently used risk stratification systems of the National Comprehensive Cancer Network guideline (NCCN-g), American Urological Association guideline (AUA-g), and European Association of Urology guideline (EAU-g), respectively. Associations between risk classification and prostate cancer-specific mortality (PCSM) were determined using Kaplan-Meier analyses and multivariable regression with Cox proportional hazards model. Area under the receiver operating characteristics curve (AUC) analyses were used to test the discrimination ability of the three risk grouping systems.

RESULTS

We analyzed 310,062 patients with a median follow-up of 61 months. A total of 36,368 deaths occurred, including 6,033 prostate cancer deaths. For all the three risk stratification systems, the risk groups were significantly associated with PCSM. The AUC of the model relying on NCCN-g, AUA-g, and EAU-g risk stratification systems for PCSM at specifically 8 years were 0.818, 0.793, and 0.689 in the entire population; 0.819, 0.795, and 0.691 in Whites; 0.802, 0.777, and 0.681 in Blacks; 0.862, 0.818, and 0.714 in Asians; 0.845, 0.806, and 0.728 in Chinese patients. Regardless of the age, marital status, socioeconomic status, and treatment modality, AUC of the model relying on NCCN-g and AUA-g for PCSM was greater than that relying on EAU-g; AUC of the model relying on NCCN-g system was greater than that of the AUA-g system.

CONCLUSIONS

The NCCN-g and AUA-g risk stratification systems perform better in discriminating PCSM compared to the EAU-g system. The discrimination ability of the NCCN-g system was better than that of the AUA-g system. It is recommended to use NCCN-g to evaluate risk groups for prostate cancer patients and then provide more appropriate corresponding treatment recommendations.

摘要

背景

尚不清楚哪种风险分层系统在预测前列腺癌死亡方面具有最佳的辨别能力。

方法

我们使用监测、流行病学和最终结果数据库,确定了2004年至2015年间诊断为非转移性原发性前列腺腺癌的患者。分别使用美国国立综合癌症网络指南(NCCN-g)、美国泌尿外科学会指南(AUA-g)和欧洲泌尿外科学会指南(EAU-g)这三种常用的风险分层系统,将患者分为不同的风险组。使用Kaplan-Meier分析和Cox比例风险模型的多变量回归确定风险分类与前列腺癌特异性死亡率(PCSM)之间的关联。使用受试者工作特征曲线(AUC)下面积分析来测试这三种风险分组系统的辨别能力。

结果

我们分析了310,062例患者,中位随访时间为61个月。共发生36,368例死亡,其中包括6,033例前列腺癌死亡。对于所有这三种风险分层系统,风险组与PCSM均显著相关。在整个队列中,依赖NCCN-g)、AUA-g和EAU-g风险分层系统的模型在8年时PCSM的AUC分别为0.818、0.793和0.689;在白人中分别为0.819、0.795和0.691;在黑人中分别为0.802、0.777和0.681;在亚洲人中分别为0.862、0.818和0.714;在中国患者中分别为0.845、0.806和0.728。无论年龄、婚姻状况、社会经济状况和治疗方式如何,依赖NCCN-g和AUA-g的模型对于PCSM的AUC均大于依赖EAU-g的模型;依赖NCCN-g系统的模型的AUC大于AUA-g系统的模型。

结论

与EAU-g系统相比,NCCN-g和AUA-g风险分层系统在辨别PCSM方面表现更好。NCCN-g系统的辨别能力优于AUA-g系统。建议使用NCCN-g来评估前列腺癌患者的风险组,然后提供更合适的相应治疗建议。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/061a/8076565/5b2be9614bf9/fonc-11-646073-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/061a/8076565/06377d469bde/fonc-11-646073-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/061a/8076565/b85d91acd048/fonc-11-646073-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/061a/8076565/a65da74cce1d/fonc-11-646073-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/061a/8076565/f9bb8d278511/fonc-11-646073-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/061a/8076565/5b2be9614bf9/fonc-11-646073-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/061a/8076565/06377d469bde/fonc-11-646073-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/061a/8076565/b85d91acd048/fonc-11-646073-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/061a/8076565/a65da74cce1d/fonc-11-646073-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/061a/8076565/f9bb8d278511/fonc-11-646073-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/061a/8076565/5b2be9614bf9/fonc-11-646073-g005.jpg

相似文献

1
Population-Based Comparison of Different Risk Stratification Systems Among Prostate Cancer Patients.前列腺癌患者中不同风险分层系统的基于人群的比较
Front Oncol. 2021 Apr 13;11:646073. doi: 10.3389/fonc.2021.646073. eCollection 2021.
2
Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.改善原发性前列腺癌诊断时的临床风险分层:一项预后建模研究。
PLoS Med. 2016 Aug 2;13(8):e1002063. doi: 10.1371/journal.pmed.1002063. eCollection 2016 Aug.
3
Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study.不同预处理风险分层工具预测前列腺癌死亡:全国队列研究中的头对头比较。
Eur Urol. 2020 Feb;77(2):180-188. doi: 10.1016/j.eururo.2019.09.027. Epub 2019 Oct 9.
4
Application of bone scans for prostate cancer staging: Which guideline shows better result?骨扫描在前列腺癌分期中的应用:哪种指南显示出更好的结果?
Can Urol Assoc J. 2014 Jul;8(7-8):E515-9. doi: 10.5489/cuaj.2054.
5
Development of a nomogram predicting metastatic disease and the assessment of NCCN, AUA and EAU guideline recommendations for bone imaging in prostate cancer patients.列线图预测前列腺癌转移疾病的发展及对 NCCN、AUA 和 EAU 指南推荐用于前列腺癌患者骨显像的评估。
World J Urol. 2021 Jun;39(6):1815-1823. doi: 10.1007/s00345-020-03363-0. Epub 2020 Jul 20.
6
A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.基于多参数磁共振成像检查结果,为国际泌尿病理学会(ISUP)分级分组(GG)1 或 ISUP GG2 前列腺癌患者制定的主动监测候选者的新型列线图。
BJU Int. 2020 Jul;126(1):104-113. doi: 10.1111/bju.15048. Epub 2020 Apr 1.
7
Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk stratification criteria for prostate cancer.前列腺癌有利的中间风险、不利的中间风险和极高风险分层标准的统一。
BJU Int. 2017 Nov;120(5B):E87-E95. doi: 10.1111/bju.13903. Epub 2017 Jun 3.
8
Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer.风险组与前列腺癌死亡:对具有有利中危前列腺癌的男性进行主动监测的影响。
JAMA Oncol. 2015 Jun;1(3):334-40. doi: 10.1001/jamaoncol.2014.284.
9
Is pelvic MRI imaging sufficient cross-sectional imaging for staging intermediate and high-risk prostate cancer?盆腔磁共振成像是否足以作为中高危前列腺癌分期的横断面成像?
Urol Oncol. 2021 Jul;39(7):433.e9-433.e15. doi: 10.1016/j.urolonc.2021.01.029. Epub 2021 Feb 17.
10
Radiotherapy of Prostate Carcinoma: A Comparison of the Predictive Role of EAU NCCN Risk Stratification Systems.前列腺癌放射治疗:EAU-NCCN 风险分层系统预测作用的比较。
Anticancer Res. 2020 Aug;40(8):4413-4418. doi: 10.21873/anticanres.14446.

引用本文的文献

1
Prostate cancer management in Southeast Asian countries: a survey of clinical practice patterns.东南亚国家的前列腺癌管理:临床实践模式调查
Ther Adv Med Oncol. 2024 Jan 18;16:17588359231216582. doi: 10.1177/17588359231216582. eCollection 2024.
2
ZNF750: A Novel Prognostic Biomarker in Metastatic Prostate Cancer.ZNF750:转移性前列腺癌的新型预后生物标志物。
Int J Mol Sci. 2023 Mar 30;24(7):6519. doi: 10.3390/ijms24076519.
3
Long-term results with custom-linked iodine-125 seeds and real-time brachytherapy in low- and intermediate-risk prostate cancer.

本文引用的文献

1
Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate.国际前列腺癌分期协作组基于疾病特异性死亡率数据制定和验证非转移性前列腺癌临床预后分期系统。
JAMA Oncol. 2020 Dec 1;6(12):1912-1920. doi: 10.1001/jamaoncol.2020.4922.
2
Intermediate-risk Prostate Cancer: Stratification and Management.中危前列腺癌:分层与管理。
Eur Urol Oncol. 2020 Jun;3(3):270-280. doi: 10.1016/j.euo.2020.03.002. Epub 2020 Apr 14.
3
A genomic and epigenomic atlas of prostate cancer in Asian populations.
定制连接碘-125种子源与实时近距离放射治疗在低危和中危前列腺癌中的长期疗效
J Contemp Brachytherapy. 2022 Jun;14(3):215-221. doi: 10.5114/jcb.2022.116150. Epub 2022 May 12.
4
Comparison of Clinical Outcomes of Radical Prostatectomy versus IMRT with Long-Term Hormone Therapy for Relatively Young Patients with High- to Very High-Risk Localized Prostate Cancer.根治性前列腺切除术与调强放射治疗联合长期激素治疗对相对年轻的高危至极高危局限性前列腺癌患者临床结局的比较
Cancers (Basel). 2021 Nov 28;13(23):5986. doi: 10.3390/cancers13235986.
亚洲人群前列腺癌的基因组和表观基因组图谱。
Nature. 2020 Apr;580(7801):93-99. doi: 10.1038/s41586-020-2135-x. Epub 2020 Mar 25.
4
Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study.不同预处理风险分层工具预测前列腺癌死亡:全国队列研究中的头对头比较。
Eur Urol. 2020 Feb;77(2):180-188. doi: 10.1016/j.eururo.2019.09.027. Epub 2019 Oct 9.
5
Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer.高危前列腺癌三分层临床分类的基因组验证。
Int J Radiat Oncol Biol Phys. 2019 Nov 1;105(3):621-627. doi: 10.1016/j.ijrobp.2019.06.2510. Epub 2019 Jul 2.
6
Circulating blood miRNAs for prostate cancer risk stratification: miRroring the underlying tumor biology with liquid biopsies.用于前列腺癌风险分层的循环血液微小RNA:通过液体活检反映潜在肿瘤生物学特性
Res Rep Urol. 2019 Feb 27;11:29-42. doi: 10.2147/RRU.S165625. eCollection 2019.
7
Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen.利用单核苷酸多态性和前列腺特异性抗原预测前列腺癌风险
J Urol. 2019 Mar;201(3):486-495. doi: 10.1016/j.juro.2018.10.015.
8
The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study.剑桥预后分组可改善原发性非转移性前列腺癌诊断时疾病死亡率的预测:验证性研究。
BMC Med. 2018 Feb 28;16(1):31. doi: 10.1186/s12916-018-1019-5.
9
Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options.临床局限性前列腺癌:AUA/ASTRO/SUO 指南。第 I 部分:风险分层、共同决策和治疗选择。
J Urol. 2018 Mar;199(3):683-690. doi: 10.1016/j.juro.2017.11.095. Epub 2017 Dec 15.
10
Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.开发和验证用于局限性前列腺癌的新型综合临床基因组风险分组分类。
J Clin Oncol. 2018 Feb 20;36(6):581-590. doi: 10.1200/JCO.2017.74.2940. Epub 2017 Nov 29.